These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
975 related articles for article (PubMed ID: 15713540)
21. Caco-2 cells and Biopharmaceutics Classification System (BCS) for prediction of transepithelial transport of xenobiotics (model drug: caffeine). Smetanova L; Stetinova V; Kholova D; Kvetina J; Smetana J; Svoboda Z Neuro Endocrinol Lett; 2009; 30 Suppl 1():101-5. PubMed ID: 20027153 [TBL] [Abstract][Full Text] [Related]
22. Validation of cell culture models for the intestine and the blood-brain barrier and comparison of drug permeation. Bock U; Flötotto T; Haltner E ALTEX; 2004; 21 Suppl 3():57-64. PubMed ID: 15057409 [TBL] [Abstract][Full Text] [Related]
23. Assessment of an in vitro blood-brain barrier model using several [Met5]enkephalin opioid analogs. Weber SJ; Abbruscato TJ; Brownson EA; Lipkowski AW; Polt R; Misicka A; Haaseth RC; Bartosz H; Hruby VJ; Davis TP J Pharmacol Exp Ther; 1993 Sep; 266(3):1649-55. PubMed ID: 8371162 [TBL] [Abstract][Full Text] [Related]
24. Transport of decursin and decursinol angelate across Caco-2 and MDR-MDCK cell monolayers: in vitro models for intestinal and blood-brain barrier permeability. Madgula VL; Avula B; Reddy V L N; Khan IA; Khan SI Planta Med; 2007 Apr; 73(4):330-5. PubMed ID: 17372866 [TBL] [Abstract][Full Text] [Related]
26. A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters. Perrière N; Yousif S; Cazaubon S; Chaverot N; Bourasset F; Cisternino S; Declèves X; Hori S; Terasaki T; Deli M; Scherrmann JM; Temsamani J; Roux F; Couraud PO Brain Res; 2007 May; 1150():1-13. PubMed ID: 17434463 [TBL] [Abstract][Full Text] [Related]
27. In vivo and in vitro evidence for nonrestricted transport of 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein tetraacetoxymethyl ester at the blood-brain barrier. Hirohashi T; Terasaki T; Shigetoshi M; Sugiyama Y J Pharmacol Exp Ther; 1997 Feb; 280(2):813-9. PubMed ID: 9023295 [TBL] [Abstract][Full Text] [Related]
28. Similar molecular descriptors determine the in vitro drug permeability in endothelial and epithelial cells. Hakkarainen JJ; Pajander J; Laitinen R; Suhonen M; Forsberg MM Int J Pharm; 2012 Oct; 436(1-2):426-43. PubMed ID: 22750947 [TBL] [Abstract][Full Text] [Related]
29. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Cucullo L; Hossain M; Rapp E; Manders T; Marchi N; Janigro D Epilepsia; 2007 Mar; 48(3):505-16. PubMed ID: 17326793 [TBL] [Abstract][Full Text] [Related]
30. Side by side comparison between dynamic versus static models of blood-brain barrier in vitro: a permeability study. Santaguida S; Janigro D; Hossain M; Oby E; Rapp E; Cucullo L Brain Res; 2006 Sep; 1109(1):1-13. PubMed ID: 16857178 [TBL] [Abstract][Full Text] [Related]
31. Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier. Murata M; Tamai I; Kato H; Nagata O; Tsuji A J Pharmacol Exp Ther; 1999 Jul; 290(1):51-7. PubMed ID: 10381759 [TBL] [Abstract][Full Text] [Related]
32. Pericyte abundance affects sucrose permeability in cultures of rat brain microvascular endothelial cells. Parkinson FE; Hacking C Brain Res; 2005 Jul; 1049(1):8-14. PubMed ID: 15935996 [TBL] [Abstract][Full Text] [Related]
33. Comparison of two blood-brain barrier in vitro systems: cytotoxicity and transfer assessments of malathion/oxon and lead acetate. Balbuena P; Li W; Magnin-Bissel G; Meldrum JB; Ehrich M Toxicol Sci; 2010 Apr; 114(2):260-71. PubMed ID: 20064834 [TBL] [Abstract][Full Text] [Related]
34. Influence of basolateral condition on the regulation of brain microvascular endothelial tight junction properties and barrier function. Colgan OC; Collins NT; Ferguson G; Murphy RP; Birney YA; Cahill PA; Cummins PM Brain Res; 2008 Feb; 1193():84-92. PubMed ID: 18177846 [TBL] [Abstract][Full Text] [Related]
35. Development and validation of a LC-MS/MS method for assessment of an anti-inflammatory indolinone derivative by in vitro blood-brain barrier models. Jähne EA; Eigenmann DE; Culot M; Cecchelli R; Walter FR; Deli MA; Tremmel R; Fricker G; Smiesko M; Hamburger M; Oufir M J Pharm Biomed Anal; 2014 Sep; 98():235-46. PubMed ID: 24949819 [TBL] [Abstract][Full Text] [Related]
36. Carrier-mediated delivery of metabotrophic glutamate receptor ligands to the central nervous system: structural tolerance and potential of the L-system amino acid transporter at the blood-brain barrier. Reichel A; Begley DJ; Abbott NJ J Cereb Blood Flow Metab; 2000 Jan; 20(1):168-74. PubMed ID: 10616805 [TBL] [Abstract][Full Text] [Related]
37. An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening. Culot M; Lundquist S; Vanuxeem D; Nion S; Landry C; Delplace Y; Dehouck MP; Berezowski V; Fenart L; Cecchelli R Toxicol In Vitro; 2008 Apr; 22(3):799-811. PubMed ID: 18280105 [TBL] [Abstract][Full Text] [Related]
38. A novel flow based hollow-fiber blood-brain barrier in vitro model with immortalised cell line PBMEC/C1-2. Neuhaus W; Lauer R; Oelzant S; Fringeli UP; Ecker GF; Noe CR J Biotechnol; 2006 Aug; 125(1):127-41. PubMed ID: 16730091 [TBL] [Abstract][Full Text] [Related]
39. Impaired induction of blood-brain barrier properties in aortic endothelial cells by astrocytes from GFAP-deficient mice. Pekny M; Stanness KA; Eliasson C; Betsholtz C; Janigro D Glia; 1998 Apr; 22(4):390-400. PubMed ID: 9517571 [TBL] [Abstract][Full Text] [Related]